The link between heightened thrombogenicity and inflammation: Pre-procedure characterization of the patient at high risk for recurrent events after stenting

Paul A. Gurbel, Kevin P. Bliden, Rolf Kreutz, Joseph Dichiara, Mark J. Antonino, Udaya S. Tantry

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Heightened thrombogenicity and biomarker evidence of inflammation have been independently associated with ischemic risk in patients with coronary artery disease. However, a study examining their relation has not been reported. We analysed the relation between measurements of thrombogenicity and biomarkers in patients undergoing stenting and followed for 24 months recurrent ischemic events. In 84 consecutive patients undergoing stenting, pre-procedure thrombogenicity was measured by thrombelastography (TEG) and conventional aggregometry whereas biomarkers were measured by fluorokine multi-analyte profiling. Patients were stratified into quartiles based on platelet-fibrin clot strength (MA) by TEG and correlated with ischemic event occurrence. Patients in the highest MA quartile (high MA) had greater ADP-induced platelet aggregation (57.5 ± 15.0% vs. 47.9 ± 17.6%, p = 0.05), C-reactive protein (25.0 ± 5.6 vs. 4.2 ± 1.0 μg/mL, p = 0.006) and interleukin-8 (23.8 ± 2.8 vs. 14.1 ± 1.6 pg/mL, p <0.001) than patients within the lowest MA quartile (low MA). Epidermal growth factor (7.7 ± 2.2 vs. 1.2 ± 0.3 pg/mL, p = 0.006) and vascular endothelial growth factor (296 ± 35 vs. 190 ± 10 pg/mL, p = 0.05) were also higher. Patients with high-MA had an ischemic event more often than patients with low-MA (48% vs. 13%, p = 0.02). Our study suggests that a link is present between inflammation and heightened thrombogenicity measured pre-procedurally in the patient at high risk for recurrent ischemic events after stenting. Larger studies are required to solidify these observations and their clinical relevance.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalPlatelets
Volume20
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Inflammation
Thrombelastography
Biomarkers
Fibrin
Interleukin-8
Platelet Aggregation
Epidermal Growth Factor
C-Reactive Protein
Adenosine Diphosphate
Vascular Endothelial Growth Factor A
Coronary Artery Disease
Blood Platelets

Keywords

  • Biomarker
  • Inflammation
  • Ischemic events
  • Platelet-fibrin clot strength
  • Stenting

ASJC Scopus subject areas

  • Hematology

Cite this

The link between heightened thrombogenicity and inflammation : Pre-procedure characterization of the patient at high risk for recurrent events after stenting. / Gurbel, Paul A.; Bliden, Kevin P.; Kreutz, Rolf; Dichiara, Joseph; Antonino, Mark J.; Tantry, Udaya S.

In: Platelets, Vol. 20, No. 2, 03.2009, p. 97-104.

Research output: Contribution to journalArticle

Gurbel, Paul A. ; Bliden, Kevin P. ; Kreutz, Rolf ; Dichiara, Joseph ; Antonino, Mark J. ; Tantry, Udaya S. / The link between heightened thrombogenicity and inflammation : Pre-procedure characterization of the patient at high risk for recurrent events after stenting. In: Platelets. 2009 ; Vol. 20, No. 2. pp. 97-104.
@article{a6d906cbb7a04182a5181693fa3708dc,
title = "The link between heightened thrombogenicity and inflammation: Pre-procedure characterization of the patient at high risk for recurrent events after stenting",
abstract = "Heightened thrombogenicity and biomarker evidence of inflammation have been independently associated with ischemic risk in patients with coronary artery disease. However, a study examining their relation has not been reported. We analysed the relation between measurements of thrombogenicity and biomarkers in patients undergoing stenting and followed for 24 months recurrent ischemic events. In 84 consecutive patients undergoing stenting, pre-procedure thrombogenicity was measured by thrombelastography (TEG) and conventional aggregometry whereas biomarkers were measured by fluorokine multi-analyte profiling. Patients were stratified into quartiles based on platelet-fibrin clot strength (MA) by TEG and correlated with ischemic event occurrence. Patients in the highest MA quartile (high MA) had greater ADP-induced platelet aggregation (57.5 ± 15.0{\%} vs. 47.9 ± 17.6{\%}, p = 0.05), C-reactive protein (25.0 ± 5.6 vs. 4.2 ± 1.0 μg/mL, p = 0.006) and interleukin-8 (23.8 ± 2.8 vs. 14.1 ± 1.6 pg/mL, p <0.001) than patients within the lowest MA quartile (low MA). Epidermal growth factor (7.7 ± 2.2 vs. 1.2 ± 0.3 pg/mL, p = 0.006) and vascular endothelial growth factor (296 ± 35 vs. 190 ± 10 pg/mL, p = 0.05) were also higher. Patients with high-MA had an ischemic event more often than patients with low-MA (48{\%} vs. 13{\%}, p = 0.02). Our study suggests that a link is present between inflammation and heightened thrombogenicity measured pre-procedurally in the patient at high risk for recurrent ischemic events after stenting. Larger studies are required to solidify these observations and their clinical relevance.",
keywords = "Biomarker, Inflammation, Ischemic events, Platelet-fibrin clot strength, Stenting",
author = "Gurbel, {Paul A.} and Bliden, {Kevin P.} and Rolf Kreutz and Joseph Dichiara and Antonino, {Mark J.} and Tantry, {Udaya S.}",
year = "2009",
month = "3",
doi = "10.1080/09537100802687666",
language = "English (US)",
volume = "20",
pages = "97--104",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The link between heightened thrombogenicity and inflammation

T2 - Pre-procedure characterization of the patient at high risk for recurrent events after stenting

AU - Gurbel, Paul A.

AU - Bliden, Kevin P.

AU - Kreutz, Rolf

AU - Dichiara, Joseph

AU - Antonino, Mark J.

AU - Tantry, Udaya S.

PY - 2009/3

Y1 - 2009/3

N2 - Heightened thrombogenicity and biomarker evidence of inflammation have been independently associated with ischemic risk in patients with coronary artery disease. However, a study examining their relation has not been reported. We analysed the relation between measurements of thrombogenicity and biomarkers in patients undergoing stenting and followed for 24 months recurrent ischemic events. In 84 consecutive patients undergoing stenting, pre-procedure thrombogenicity was measured by thrombelastography (TEG) and conventional aggregometry whereas biomarkers were measured by fluorokine multi-analyte profiling. Patients were stratified into quartiles based on platelet-fibrin clot strength (MA) by TEG and correlated with ischemic event occurrence. Patients in the highest MA quartile (high MA) had greater ADP-induced platelet aggregation (57.5 ± 15.0% vs. 47.9 ± 17.6%, p = 0.05), C-reactive protein (25.0 ± 5.6 vs. 4.2 ± 1.0 μg/mL, p = 0.006) and interleukin-8 (23.8 ± 2.8 vs. 14.1 ± 1.6 pg/mL, p <0.001) than patients within the lowest MA quartile (low MA). Epidermal growth factor (7.7 ± 2.2 vs. 1.2 ± 0.3 pg/mL, p = 0.006) and vascular endothelial growth factor (296 ± 35 vs. 190 ± 10 pg/mL, p = 0.05) were also higher. Patients with high-MA had an ischemic event more often than patients with low-MA (48% vs. 13%, p = 0.02). Our study suggests that a link is present between inflammation and heightened thrombogenicity measured pre-procedurally in the patient at high risk for recurrent ischemic events after stenting. Larger studies are required to solidify these observations and their clinical relevance.

AB - Heightened thrombogenicity and biomarker evidence of inflammation have been independently associated with ischemic risk in patients with coronary artery disease. However, a study examining their relation has not been reported. We analysed the relation between measurements of thrombogenicity and biomarkers in patients undergoing stenting and followed for 24 months recurrent ischemic events. In 84 consecutive patients undergoing stenting, pre-procedure thrombogenicity was measured by thrombelastography (TEG) and conventional aggregometry whereas biomarkers were measured by fluorokine multi-analyte profiling. Patients were stratified into quartiles based on platelet-fibrin clot strength (MA) by TEG and correlated with ischemic event occurrence. Patients in the highest MA quartile (high MA) had greater ADP-induced platelet aggregation (57.5 ± 15.0% vs. 47.9 ± 17.6%, p = 0.05), C-reactive protein (25.0 ± 5.6 vs. 4.2 ± 1.0 μg/mL, p = 0.006) and interleukin-8 (23.8 ± 2.8 vs. 14.1 ± 1.6 pg/mL, p <0.001) than patients within the lowest MA quartile (low MA). Epidermal growth factor (7.7 ± 2.2 vs. 1.2 ± 0.3 pg/mL, p = 0.006) and vascular endothelial growth factor (296 ± 35 vs. 190 ± 10 pg/mL, p = 0.05) were also higher. Patients with high-MA had an ischemic event more often than patients with low-MA (48% vs. 13%, p = 0.02). Our study suggests that a link is present between inflammation and heightened thrombogenicity measured pre-procedurally in the patient at high risk for recurrent ischemic events after stenting. Larger studies are required to solidify these observations and their clinical relevance.

KW - Biomarker

KW - Inflammation

KW - Ischemic events

KW - Platelet-fibrin clot strength

KW - Stenting

UR - http://www.scopus.com/inward/record.url?scp=61649124757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649124757&partnerID=8YFLogxK

U2 - 10.1080/09537100802687666

DO - 10.1080/09537100802687666

M3 - Article

C2 - 19235051

AN - SCOPUS:61649124757

VL - 20

SP - 97

EP - 104

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 2

ER -